Evidence map›Paper›PMID 40186516›Full record

ArticleEpilepsia open2025

Efficacy of phenobarbital is maintained after exposure to mild-to-moderate seizures in neonates.

Cynthia Sharpe, Charlotte-Rose Rennie-Younger, Dug Yeo Han, Suzanne L Davis, Mark Nespeca, Francesco Pisani, Jeffrey J Gold, Gail E Reiner, Sonya Wang, Richard H Haas

Abstract read
In one paragraph

Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Rethinking the definition of neonatal status epilepticus.European journal of pediatrics · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cynthia SharpeDepartment of Paediatric Neurology, Starship Children's Health, Auckland, New Zealand.
Charlotte-Rose Rennie-YoungerDepartment of Paediatric Neurology, Starship Children's Health, Auckland, New Zealand.
Dug Yeo HanStarship Research and Innovation, Starship Foundation, Auckland, New Zealand.
Suzanne L DavisDepartment of Paediatric Neurology, Starship Children's Health, Auckland, New Zealand.
Mark NespecaDepartment of Neurosciences, University of California San Diego, Rady Children's Hospital San Diego, San Diego, California, USA.
Francesco PisaniDepartment of Neuroscience, Sapienza University, Rome, Italy.
Jeffrey J GoldDepartment of Neurosciences, University of California San Diego, Rady Children's Hospital San Diego, San Diego, California, USA.
Gail E ReinerDepartment of Neurosciences, University of California San Diego, Rady Children's Hospital San Diego, San Diego, California, USA.
Sonya WangDepartment of Pediatric Neurology, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
Richard H HaasDepartment of Neurosciences, University of California San Diego, Rady Children's Hospital San Diego, San Diego, California, USA.

Funding

FDA HHS R01 FD004147FDA HHS R01 FD006335U.S. Food and Drug Administration RO1FD004147
6 · The paper itself

Abstract

To study the relationship between the delay in treatment and the efficacy of phenobarbital in neonates, we re-analyzed data from the NEOLEV2 study. Continuous video EEG (cEEG) from patients treated with phenobarbital was reviewed by neurophysiologists who marked each seizure. The time from seizure onset to phenobarbital, total seizure burden pre-phenobarbital, and maximum seizure density (summed seizure burden per hour) pre-phenobarbital were calculated and correlated with phenobarbital efficacy at 20 mg/kg and at 40 mg/kg. The time between seizure onset and phenobarbital treatment did not predict refractoriness to phenobarbital. However, the maximum seizure density per hour and total seizure burden before phenobarbital treatment were strongly correlated with efficacy. ROC curve analysis showed cut-offs of maximum seizure density pre-phenobarbital of 10 ½ min/h and total seizure burden pre-phenobarbital of 36 ¼ min had excellent discriminatory ability in separating patients in whom phenobarbital would be effective from patients in whom it would not be effective (AUC 0.84, p = 0.0002 and AUC 0.85, p = 0.0051). These data suggest that whereas neonates with high seizure density must be treated as an emergency, mild-to-moderate seizures remain responsive to phenobarbital if treated within a time frame of several hours. PLAIN LANGUAGE SUMMARY: Phenobarbital is very effective at stopping seizures in newborns. But if phenobarbital is given after many hours of seizures, it becomes less effective. We do not know how quickly this happens. Our study found that it does not happen over the short term (<4 h). It is more difficult to stop seizures that cumulatively last more than 10 min/h.

Indexed as

AnticonvulsantsPhenobarbitalSeizuresElectroencephalographyFemaleHumansInfant, NewbornMaleTreatment OutcomeAnticonvulsantsPhenobarbitalcontinuous EEG monitoringhypoxic ischemic encephalopathyneonatal seizuresphenobarbitalseizure

Identifiers

PMID40186516
PMCPMC12163520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.